Stephen Bagley, MD, MSCE
2 clinical trials · Sponsor
◉ Watch Stephen Bagley, MD, MSCE
| Record | Firm | Date |
|---|---|---|
| All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma (NCT05345002) | Stephen Bagley, MD, MSCE | 2022-11-16 |
| Abemaciclib in Patients with Oligodendroglioma (NCT03969706) | Stephen Bagley, MD, MSCE | 2019-05-15 |
Track Stephen Bagley, MD, MSCE automatically
Every clearance here is in the API, with alerts when new ones post.